Brief: Alpha Tau Announces Highly Promising Interim Results From Safety And Feasibility Trial Of Alpha Dart Treatment Of Advanced Pancreatic Cancer
28/11/2023 15:30
Alpha Tau Medical Ltd DRTS.O :
* ALPHA TAU ANNOUNCES HIGHLY PROMISING INTERIM RESULTS FROM
SAFETY
AND FEASIBILITY TRIAL OF ALPHA DART TREATMENT OF ADVANCED
PANCREATIC CANCER
* ALPHA TAU - ALPHA DART PROCEDURE WAS DEEMED TECHNICALLY
SUCCESSFUL IN ALL FIVE CASES, WITH ALPHA DART SOURCES
SUCCESSFULLY INSERTED INTO TARGET TUMOR
* ALPHA TAU MEDICAL LTD - NO REPORTED SERIOUS ADVERSE EVENTS
DEEMED RELATED TO PRODUCT
Source text for Eikon: ID:nGNXgWnfy
Further company coverage: DRTS.O
Recent news on Alpha Tau Medical
See all newsBrief: Alpha Tau Completes Patient Enrollment In Its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal Of FDA Approval Of Alpha Dart® To Treat Recurrent Cutaneous Squamous Cell Carcinoma
Brief: Alpha Tau Announces 100% Local Disease Control Rate And Favorable Safety Profile Observed In Alpha Dart® Pancreatic Cancer Trials Presented At Ddw 2026
Brief: Alpha Tau Medical Files To Offer Up To $300 Million In Securities - SEC Filing
Brief: Alpha Tau Announces First-Ever Oral Presentation Of Alpha Dart® Pancreatic Cancer Data At Digestive Disease Week (Ddw) 2026
Brief: Alpha Tau Medical Receives Japanese Marketing Approval For Alpha Dart In Head And Neck Cancer